Physicians Formula Holdings, Inc.

Robbins Umeda LLP Announces an Investigation of Physicians Formula Holdings, Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by members of the board of directors of Physicians Formula Holdings, Inc. (NASDAQ: FACE) in connection with their efforts to sell the company to affiliates of Swander Pace Capital.  Concerned shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly.  You can also contact attorney Gregory E. Del Gaizo at (800) 350-6003.

On August 15, 2012, Physicians Formula announced that it had entered into a definitive merger agreement to be acquired by Swander Pace.  According to the terms of the deal, Swander Pace will acquire Physicians Formula for $4.25 per share in cash.  The acquisition has already been approved by the board of directors of Physicians Formula.  Upon close of the merger, which is expected to occur later this year, Physicians Formula will be privately owned and will continue to be operated by the company’s current management team and employees.

Robbins Umeda LLP’s investigation focuses on whether the board of directors at Physicians Formula is undertaking a fair process to obtain maximum value and adequately compensate its shareholders, or seeking to benefit themselves.  At least one analyst, at Imperial Capital, has set a price target for Physician Formula at $5.00 per share, higher than the current offer of $4.25 per share.

Moreover, on August 14, 2012, Physicians Formula reported financial results for the second quarter of 2012 that exceeded analyst projections and represented substantial increases over 2011 figures.  Specifically, Physicians Formula reported a total earnings per share of $0.13, which beat analyst estimates of $0.028 by 364%.  Further, total revenue for the quarter of $26.1 million represents an increase of 25.2% over total revenues of $20.9 million during the same quarter of the previous year.  In addition, net income was $2 million compared to a net loss of $0.3 million for the same quarter in 2011. 

Given these impressive financial results and higher target price, Robbins Umeda LLP is examining the board’s decision to sell Physicians Formula now rather than allow shareholders to continue to participate in the company’s continued success and future growth prospects. 

Robbins Umeda LLP attorneys highlight that Physicians Formula shareholders have the option to file a class action lawsuit against the company to secure the best possible price for the company’s shareholders and the disclosure of material information to shareholders so they can vote on the transaction in an informed manner.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Address City State/Province *
ZIP/Postal Code Country/Region Phone *
E-mail * Confirm: E-mail *

Shares Purchased:
Number of Shares: Buy Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Shares Sold:
Number of Shares: Buy Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Please Note: Neither the submission to nor the receipt of information by Robbins Umeda LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information

    Send This Post

    Tags: